CTRI/2024/05/067935尚未招募3 期
A Randomized, Open label Controlled, Single center Clinical study to evaluate the efficacy and tolerability of Herbal toothpaste (SST/SW/05/2024/01) for its Tooth whitening effect in comparison to regular conventional toothpaste in healthy human participants. - NI
Sriveda Sattva Private Limited Sri Sri Tattva0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects were required to be in good general health, between 18 and 65 years of age.
- •2.Patient willing to offer informed consent and comply with research protocol.
- •3. Subjects were required to be willing to refrain from using chlorhexidene and or Listerine or any mouth washes which are expected to cause dental staining
- •4.The subjects were also required to have visible stain on four of the six maxillary anterior teeth and to have at least four of the eight central and lateral incisors with individual Lobene scores greeter than1.5.
- •5.Presence of extrinsic stains.
- •6.Atleast 8 of the anterior teeth should be without restoration, no oral prosthesis, no untreated caries
- •7.Not currently participating in any other clinical trial
排除标准
- •1.Generalized recession of the gingiva (obvious periodontal disease).
- •2. Generalized malocclusion or overlapping of teeth, anterior teeth caries, severe attrition and abrasion in anterior teeth
- •3. Inability to comply with brushing instructions (e.g., dexterity or comprehension issues).
- •4. Pregnant and lactating mothers
- •5. Person suffering from neurological or psychiatric disorders.
- •6. Patients suffering from systemic and oral diseases.
- •7. Individuals with history of present antibiotics and vitamins in form of chewable tablet causing dental staining during use.
- •9. Patients with history of allergy to herbal drugs, mouth washes, tooth pastes or any other oral hygiene products.
- •10.Subjects with intrinsic stain in anterior teeth
- •11. Subjects with a history of consuming tobacco chewing or smoking/chronic betal nut chewing/other regular chewing gums.
- •12. Individuals already using any form of tooth whitening tooth paste.
- •13.Participation in clinical pharmacology trial during previous three months.
- •14.Dental treatment during the period of clinical trial.
研究者
相似试验
已完成
不适用
Clinical study to assess effectiveness and safety of ayurvedic products ostikot tablet, rhukot plus cream and rhukot liniment in patients with osteo arthritis of kneeCTRI/2015/02/005489Clinfound Clinical Research Services PvtLtd75
进行中(未招募)
1 期
RAPID-1 Diabetic Foot Ulcer Randomised Controlled StudyEUCTR2018-003596-36-GBBiotherapy Services Ltd.66
已完成
不适用
A single center, randomized, open-label, controlled, three-arm study to evaluate the effect of a new combined oral contraceptive (COC) containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of two reference COCs containing either 30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG) or 20 mcg EE and 3 mg DRSP on endocrine function, metabolic control and hemostasis during 6 treatment cyclesContraceptionbirth controlNL-OMON43221Estetra SPR100
进行中(未招募)
不适用
A single-center, open-label, controlled, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) as compared to a sequential oral contraceptive containing ethinylestradiol and levonorgestrel (SH D00264A) on plasma lipids, hemostatic variables, and carbohydrate metabolism in 60 healthy female volunteers aged 18-50 years over 7 treatment cycles - Metabolism study vs Triquilar 21+7ContraceptionEUCTR2004-001614-13-DESchering AG60
进行中(未招募)
1 期
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 17.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000601-74-HUJanssen-Cilag International NV280
